As the Quest for a Miracle Weight-Loss Drug Continues, Eli Lilly and Company Seems to Have an Edge Over Novo Nordisk’s Ozempic
This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.
Americans are among the least healthy first-world citizens, partly due to the fact that over 42 percent of the adults in the US suffer from obesity – a condition that is an ideal breeding ground for a veritable host of ailments, including hypertension, diabetes, coronary heart disease, osteoarthritis, sleep apnea, etc. Luckily, we are currently at the precipice of slaying this menace for good, all thanks to a range of new drugs, including Novo Nordisk’s Ozempic (semaglutide; the drug’s other, teen-focused variant is known as Wegovy) and Eli Lilly and Company’s Mounjaro (Tirzepatide) as well as Retatrutide.
Novo Nordisk’s Ozempic was approved by the FDA in 2017 for patients with type-2 diabetes. In December 2022, the FDA approved Ozempic’s new variant – Wegovy – to treat obesity in teens aged 12 years and above. Critically, clinical trials showed that patients taking Wegovy regularly could lose around 15 percent of their body weight. Both Ozempic and Wegovy mimic the hormone glucagon-like peptide-1 (GLP-1), which targets brain areas that regulate appetite.
Eli Lilly and Company has emerged as a significant player in the weight-loss arena in recent years. The FDA approved the company’s Mounjaro injections in 2022 to treat type-2 diabetes in conjunction with obesity. Mounjaro targets two hormones – GLP-1 as well as glucose-dependent insulinotropic polypeptide (GIP) – to achieve superior blood sugar control. When used in conjunction with insulin, clinical trials showed an average weight loss of 23 pounds.
Of course, it is Eli Lilly and Company’s latest offering that is creating a lot of
Read more on wccftech.com
